Showing results (21-30 of 74) with videos related to

Sort By:
Pageof 8
Critical Care Medicine|May 3, 2021
Extracorporeal Cytokine Adsorption Therapy As a Preventive Measure in Cardiac Surgery and As a Therapeutic Add-On Treatment in Sepsis: An Updated Systematic Review of Comparative Efficacy and SafetyGregor Goetz, Katharina Hawlik, Claudia Wild
BMC Cardiovascular Disorders|November 5, 2014
Contrasting clinical evidence for market authorisation of cardio-vascular devices in Europe and the USA: a systematic analysis of 10 devices based on Austrian pre-reimbursement assessmentsClaudia Wild, Judit Erdös, Ingrid Zechmeister
International Journal of Technology Assessment in Health Care|December 21, 2017
ANALYSIS OF DUPLICATION AND TIMING OF HEALTH TECHNOLOGY ASSESSMENTS ON MEDICAL DEVICES IN EUROPEKatharina Hawlik, Patrick Rummel, Claudia Wild
BMC Gastroenterology|August 17, 2022
Clinical effectiveness and safety of self-expandable implantable bulking agents for faecal incontinence: a systematic reviewLucia Gassner, Claudia Wild, Melanie Walter
Wiener Medizinische Wochenschrift (1946)|March 12, 2008
[Systematic reviews and meta-analysis]Gerald Gartlehner, Claudia Wild, Philipp Mad
Journal of Pharmaceutical Policy and Practice|August 7, 2025
The origins of Novo Nordisk and Novartis products: piloting a framework to identify the public contributionsDaniel Fabian, Ozren Sehic, Claudia Wild
International Journal of Cardiology. Heart & Vasculature|April 7, 2023
Wearable cardioverter defibrillator for preventing sudden cardiac death in patients at risk: An updated systematic review of comparative effectiveness and safetyGregor Goetz, Bernhard Wernly, Claudia Wild
European Journal of Cancer Care|February 8, 2021
Cancer care near the end-of-life in Austria: A retrospective data analysisMartin Robausch, Nicole Grössmann, Claudia Wild
European Journal of Paediatric Neurology : EJPN : Official Journal of the European Paediatric Neurology Society|June 21, 2024
An updated systematic review on spinal muscular atrophy patients treated with nusinersen, onasemnogene abeparvovec (at least 24 months), risdiplam (at least 12 months) or combination therapiesDoris Giess, Judit Erdos, Claudia Wild
Health Policy (Amsterdam, Netherlands)|June 27, 2016
Factors influencing coverage decisions on medical devices: A retrospective analysis of 78 medical device appraisals for the Austrian hospital benefit catalogue 2008-2015Agnes Kisser, Heinz Tüchler, Judit Erdös, et al.
Pageof 8